Long-term Real-life Glycemic Outcomes with Hybrid Closed-Loop System when Compared with Sensor-Augmented Pump Therapy in Patients with Type 1 Diabetes.
To compare glycemic metrics at 3 and 6 months in patients with type 1 diabetes on 670G hybrid closed-loop (HCL) system after using a sensor-augmented pump (SAP) for at least 3-months. This is a retrospective study from a center that has the largest 670G users in the USA. Data from 202 SAP users were reviewed. Sixty one patients were excluded (2 steroid use, 4 pregnancy, 27 previous Enlite user, 28 non-continuous use of 670G). Out of 141 patients that met inclusion criteria, 127 (21-68 years old) had complete data. HbA1c levels decreased by 0.4% at 3 months and were maintained at 6 months (7.6 ± 0.07 vs 7.2 ± 0.08, p<0.001) with no weight gain at 6 months. Time-in-range (70-180 mg/dL) increased from 59.5% ± 1.1% to 70.2% ± 1.2% and 70.1% ± 1.1% at 3 months and 6 months (p<0.001), respectively. At 6 months, time spent in hypoglycemia (<70 mg/dl) and time spent in hyperglycemia (>180 mg/dl) were reduced by 30% (2.2% ± 0.2% vs.3.2% ± 0.2%; p<0.05) and 26% (28.3% ± 1.2% vs. 38.1% ± 1.2%; p<0.001) respectively. More time in auto-mode was associated with improved CGM metrics, lower HbA1c, decreased glycemic variability. Time in auto-mode declined in men after 3 months, while women maintained similar auto-mode use throughout the study. The HCL system improved HbA1c levels and time-in-range, and decreased time spent in hypo- and hyperglycemia at 6 months. Auto-mode use was significantly correlated with CGM metrics and glycemic outcomes. This article is protected by copyright. All rights reserved.